Company: KROS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001664710-25-000070
Chunk: 408

Company: Keros Therapeutics, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 8
Chunk 408
---
 changes in estimates as to financial results, development timelines or recommendations by securities analysts; 

■commencement or termination of collaboration, licensing or similar arrangements for our development programs; 

■announcements by our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments; 

■failure or discontinuation of any of our development programs; 

■results of clinical trials of product candidates of our competitors; 

■regulatory or legal developments in the United States and other countries; 

■developments or disputes concerning patent applications, issued patents or other proprietary rights; 

■the recruitment or departure of key personnel; 

■the level of expenses related to the development of KER-065, elritercept and any other product candidate we may develop; 

■variations in our financial results or those of companies that are perceived to be similar to us; 

■announcements or expectations of additional financing efforts by us; 

■sales of our common stock by us, our insiders or other stockholders; 

■recommendations and changes in estimates or recommendations by securities analysts, if any, that cover our stock; 

■changes in the structure of healthcare payment systems; 

■market conditions in the pharmaceutical and biotechnology sectors; 

■general economic, political, and market conditions and overall fluctuations in the financial markets in the United States and abroad, such as potential future disruptions in access to bank deposits or lending commitments due to bank failures; and 

■investors’ general perception of us and our business. 

The stock market in general, and the markets for pharmaceutical, biopharmaceutical and biotechnology stocks in particular, have experienced extreme price and volume fluctuations that have been often unrelated or disproportionate to the operating performance of the issuer. In addition, the trading prices for common stock of other pharmaceutical, biopharmaceutical and biotechnology companies have been highly volatile as a result of public health crises, geopolitical tensions, a resulting global slowdown of economic activity, increased inflation, tariffs and other adverse effects or developments. The extent to which these factors may impact our business, preclinical studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence. 

These and other market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance, which may negatively affect the liquidity of our common stock. 

We could be subject to securities class action litigation. 

82

In the past, securities class action litigation has often been brought against public companies following